NY-FIRST-EAGLE-INV-MGMT
3.8.2020 12:02:05 CEST | Business Wire | Press release
First Eagle Investment Management, LLC (“First Eagle”) is pleased to announce plans to open a branch of First Eagle Investment Management Ltd. in Munich, Germany, through which the firm will serve international wholesale clients in Europe, the Middle East and Africa (EMEA) as well as in other non-US domiciles. The Munich office will be overseen by Matthieu Louanges, who joins First Eagle on August 3 as head of its international wholesale business. Louanges will be stationed in Munich in preparation for the official opening of First Eagle’s office there, expected in late 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005114/en/
“First Eagle traces its origin to Germany, and we are excited to reestablish our local presence there after an absence of more than 80 years,” said Mehdi Mahmud, President and Chief Executive Officer of First Eagle. “Arnhold and S. Bleichroeder, the predecessor firm to First Eagle, represented the amalgamation of two storied German banks: Berlin-based S. Bleichroeder, founded in 1803, and Dresden-based Gebr. Arnhold, founded in 1864. First Eagle’s European roots run deep, and the plan to open an office in continental Europe feels like something of a homecoming. Under the leadership of Matthieu, who has extensive experience working with international clients and building and managing multinational franchises, our Munich location will help us strengthen our partnership with Amundi Asset Management and enhance our client service outreach for non-US clients worldwide.”
Louanges and his team, located in Munich and New York, will be responsible for First Eagle’s international wholesale distribution business, which includes the firm’s distribution partnership with Amundi Asset Management. The European Union and the European continent will continue to be key elements of First Eagle’s international business, and the firm expects Asia and South America to be particularly important regions of business growth moving forward. Highlighting the firm’s commitment to its international business, Louanges will report to Mahmud and will join First Eagle’s Management Committee, marking the first time a Management Committee member has been based outside of the US.
French/German binational Louanges joins First Eagle after more than 20 years at PIMCO, where he was one of the most senior leaders in PIMCO’s EMEA franchise; as Managing Director, he most recently headed up the firm’s global relationship with Allianz. Earlier in his PIMCO tenure, Louanges launched the company’s EMEA insurance channel, which over time evolved into the broader financial institutions group, and he had broad oversight responsibility for PIMCO’s business in Switzerland and France as well as its EMEA client solutions team. Louanges joined PIMCO as a portfolio manager of mutual funds and institutional mandates in 2000 upon its acquisition by Allianz, where he had been playing a similar role.
“I am excited to join First Eagle Investment Management and become a member of its Management Committee,” said Louanges. “While First Eagle’s investment proposition already has a broad client base globally, given the increasingly uncertain economic and market environment, there remains a strong appetite for solutions that combine the potential for attractive returns with downside protection over full market cycles. I look forward to working closely with Mehdi and the rest of my new colleagues to make First Eagle’s time-tested, differentiated investments solutions accessible to international clients and to support our important partnership with Amundi Asset Management.”
Louanges succeeds Robert H. Hackney, Jr., a 25-year veteran of First Eagle. Hackney will remain with the firm, first to assist in the transition of his leadership of the international wholesale distribution business to Louanges and afterward as an advisor to Mahmud and the firm’s leadership team on strategic initiatives. “Robert’s leadership has been integral to the success of our partnership with Amundi Asset Management and our international wholesale business. We have benefited from his keen strategic perspective over the years, and I look forward to his ongoing counsel as we continue to evolve the firm,” said Mahmud.
ABOUT FIRST EAGLE INVESTMENT MANAGEMENT
First Eagle Investment Management is an independent, privately owned investment management firm headquartered in New York with approximately $101 billion in assets under management as of June 30, 2020. Dedicated to providing prudent stewardship of client assets, the firm focuses on active, fundamental and benchmark-agnostic investing, with a strong emphasis on downside protection. Over a long history dating back to 1864, First Eagle has helped its clients avoid permanent impairment of capital and earn attractive returns through widely varied economic cycles—a tradition that is central to its mission today. The firm’s investment capabilities include equity, fixed income, alternative credit and multi-asset strategies. For more information on First Eagle, please visit www.feim.com . For information on First Eagle Alternative Credit, please visit www.feac.com .
First Eagle Investment Management is the brand name for First Eagle Investment Management, LLC and its subsidiary investment advisers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
